Aliases & Classifications for Mood Disorder

MalaCards integrated aliases for Mood Disorder:

Name: Mood Disorder 12 14
Mood Disorders 52 41 42 69
Episodic Mood Disorder 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3324
MeSH 42 D019964
NCIt 47 C92200
UMLS 69 C0525045

Summaries for Mood Disorder

MedlinePlus : 41 most people feel sad or irritable from time to time. they may say they're in a bad mood. a mood disorder is different. it affects a person's everyday emotional state. nearly one in ten people aged 18 and older have mood disorders. these include depression and bipolar disorder (also called manic depression). mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. treatments include medication, psychotherapy, or a combination of both. with treatment, most people with mood disorders can lead productive lives.

MalaCards based summary : Mood Disorder, also known as mood disorders, is related to anosognosia and endotheliitis, and has symptoms including alexithymia and psychiatric symptom. An important gene associated with Mood Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Valproic Acid and Amitriptyline have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves an excessive, irrational dread of everyday situations.

Wikipedia : 72 Mood disorder is a group of diagnoses in the Diagnostic and Statistical Manual of Mental Disorders (DSM)... more...

Related Diseases for Mood Disorder

Diseases related to Mood Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
id Related Disease Score Top Affiliating Genes
1 anosognosia 30.5 COMT DRD2 HTR1A SLC6A4
2 endotheliitis 30.4 BDNF TH
3 personality disorder 29.5 BDNF COMT CRH DISC1 DRD2 DRD4
4 schizophrenia 29.3 BDNF CACNA1C COMT DISC1 DRD2 DRD4
5 obsessive-compulsive personality disorder 29.1 BDNF COMT HTR1A HTR1B HTR2A MAOA
6 bipolar disorder 11.1
7 delusional disorder 11.1
8 schizoaffective disorder 11.0
9 panic disorder 10.9
10 conjunctival degeneration 10.9 HTR1A HTR2A SLC6A4
11 neurogenic bladder 10.9 HTR2A MAOA SLC6A4
12 polycystic ovary syndrome 10.9
13 postpartum depression 10.9
14 tinea pedis 10.9 HTR1A MAOA SLC6A4
15 ornithosis 10.9 DRD2 MAOA SLC6A4
16 splenic abscess 10.9 DRD2 HTR2A SLC6A4
17 hyperthyroxinemia 10.9 DRD2 HTR2A SLC6A4
18 paranoid personality disorder 10.9 HTR1A HTR2A
19 teebi kaurah syndrome 10.9 COMT DRD2 HTR2A
20 angiokeratoma of mibelli 10.9 HTR1A MAOA SLC6A4
21 eosinophilia-myalgia syndrome 10.9 BDNF DRD2 DRD4
22 ulcerative colitis 10.9 BDNF COMT DRD2
23 placenta disease 10.9 DRD2 DRD4 TH
24 multiple personality disorder 10.9 DRD4 MAOA MAOB
25 allergic hypersensitivity disease 10.9 DRD2 HTR1A HTR2A
26 vascular cancer 10.8 DRD2 HTR1A HTR2A
27 uterus intravascular leiomyomatosis 10.8 COMT HTR1A MAOA SLC6A4
28 polyneuropathy 10.8 HTR1A HTR2A
29 transsexualism 10.8 BDNF CREB1 HTR1A
30 brain meningioma 10.8 BDNF COMT DRD2
31 anodontia 10.8 HTR1A HTR1B SLC6A4
32 pompholyx 10.8 DRD2 HTR1A HTR2A SLC6A4
33 hodgkin's granuloma 10.8 HTR1A HTR2A
34 alcoholic liver cirrhosis 10.8 BDNF DRD2 DRD4 SLC6A4
35 luxation of globe 10.8 HTR1A NPY SLC6A4
36 pyogenic arthritis, pyoderma gangrenosum and acne 10.8 MAOA MAOB TH
37 c8 deficiency, type ii 10.8 COMT CREB1 DRD2 DRD4
38 conjunctival pigmentation 10.8 CRH MAOA MAOB SLC6A4
39 actinobacillosis 10.8 CRH NR3C1 POMC
40 osteogenesis imperfecta, type ix 10.8 BDNF COMT DRD2 DRD4
41 west syndrome 10.7 BDNF NPY TH
42 amyloidosis, finnish type 10.7 COMT MAOA MAOB TH
43 intrahepatic gall duct cancer 10.7 BDNF COMT HTR2A MAOA SLC6A4
44 ring chromosome 14 syndrome 10.7 COMT MAOA
45 pituitary adenoma, acth-secreting 10.7
46 dysthymic disorder 10.7
47 47,xyy syndrome 10.7
48 primary angle-closure glaucoma 10.7 BDNF COMT HTR1A HTR2A SLC6A4
49 trabecular follicular adenocarcinoma 10.7 CRH NR3C1 POMC
50 acute female pelvic peritonitis 10.7 DRD2 POMC SLC6A4

Comorbidity relations with Mood Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety Disorder
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Hypothyroidism Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Schizophreniform Disorder

Graphical network of the top 20 diseases related to Mood Disorder:



Diseases related to Mood Disorder

Symptoms & Phenotypes for Mood Disorder

UMLS symptoms related to Mood Disorder:


alexithymia, psychiatric symptom

MGI Mouse Phenotypes related to Mood Disorder:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 MAOA MAOB NPY NR3C1 POMC SLC18A2
2 homeostasis/metabolism MP:0005376 10.36 COMT CREB1 CRH DISC1 DRD2 DRD4
3 cardiovascular system MP:0005385 10.29 COMT CREB1 DRD2 HTR1A HTR1B MAOA
4 growth/size/body region MP:0005378 10.25 BDNF CREB1 CRH DISC1 DRD2 HTR1B
5 endocrine/exocrine gland MP:0005379 10.23 BDNF CACNA1C COMT CREB1 CRH DRD2
6 nervous system MP:0003631 10.19 BDNF CACNA1C COMT CREB1 CRH DISC1
7 integument MP:0010771 10.02 CRH DRD2 NR3C1 POMC SLC6A4 TH
8 adipose tissue MP:0005375 9.99 CRH DRD2 NPY NR3C1 POMC TPH1
9 muscle MP:0005369 9.97 CREB1 DRD2 HTR1B HTR2A NR3C1 SLC18A2
10 no phenotypic analysis MP:0003012 9.76 BDNF CRH DRD2 HTR1A HTR1B NR3C1
11 renal/urinary system MP:0005367 9.5 COMT CRH DRD2 MAOB NPY NR3C1
12 respiratory system MP:0005388 9.23 DRD2 NR3C1 TH TPH1 BDNF COMT

Drugs & Therapeutics for Mood Disorder

Drugs for Mood Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 727)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
2
Amitriptyline Approved Phase 4,Phase 3,Phase 2 50-48-6 2160
3
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
4
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-41-2 439260
5
Nortriptyline Approved Phase 4,Phase 1,Phase 2 72-69-5 4543
6
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
7
Perphenazine Approved Phase 4,Phase 3,Phase 2 58-39-9 4748
8
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 79617-96-2 68617
9
Trimipramine Approved Phase 4 739-71-9 5584 4055
10
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
11
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
12
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
13
Methyltestosterone Approved Phase 4,Phase 3 58-18-4 6010
14
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
15
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
16
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 6740-88-1 3821
17
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
18
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
19
Mianserin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 24219-97-4 4184
20
Mirtazapine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 85650-52-8, 61337-67-5 4205
21
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-23-7 5754 657311
22
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
23
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
24
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Phase 2 54739-18-3 3404 5324346
25
Trazodone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 19794-93-5 5533
26
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
27
Tranylcypromine Approved Phase 4,Phase 1,Phase 2,Early Phase 1 155-09-9 441233
28
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
29
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
30
Rasagiline Approved Phase 4 136236-51-6 3052776
31
Copper Approved Phase 4 7440-50-8 27099
32
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
33
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1 57-63-6 5991
34
Norethindrone Approved Phase 4 68-22-4 6230
35
Reboxetine Approved, Investigational Phase 4,Phase 2,Phase 1 98769-81-4, 71620-89-8 123628 65856
36
Eszopiclone Approved Phase 4,Phase 3 138729-47-2 969472
37
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 298-46-4 2554
38
Coal tar Approved Phase 4,Phase 2 8007-45-2
39
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 132539-06-1 4585
40
Oxcarbazepine Approved Phase 4 28721-07-5 34312
41
Ziprasidone Approved Phase 4,Phase 2,Phase 3 146939-27-7 60854
42
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 113-45-1 4158
43
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 106266-06-2 5073
44
Acamprosate Approved, Investigational Phase 4,Phase 1,Phase 2 77337-76-9 71158
45
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
46
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
47
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10118-90-8 5281021
48
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
49
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
50
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59467-70-8 4192

Interventional clinical trials:

(show top 50) (show all 3997)

id Name Status NCT ID Phase Drugs
1 Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) Unknown status NCT01272531 Phase 4 Mood stabilizer treatment
2 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
3 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
4 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
5 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
6 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
7 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
8 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
9 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
10 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
11 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
12 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
13 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
14 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
15 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
16 Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
17 The Effect of Duloxetine on Interoceptive Awareness Unknown status NCT00337012 Phase 4
18 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4 Sertralin;Placebo
19 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
20 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
21 Morbidity and Mortality Among Dialysis Patients After Treatment for Depression Unknown status NCT00442429 Phase 4
22 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
23 Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
24 Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
25 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
26 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
27 Lithium and Standard Therapy in Resistant Depression Unknown status NCT00927550 Phase 4 lithium;usual care
28 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4 Bupropion
29 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
30 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
31 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
32 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
33 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4 Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
34 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
35 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
36 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
37 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
38 Tranylcypromine Treatment of Bipolar Depression Unknown status NCT01430455 Phase 4 Tranylcypromine
39 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
40 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
41 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
42 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
43 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
44 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4 Rasagiline;Placebo
45 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
46 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
47 Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales Unknown status NCT02210702 Phase 4 Ethinyl Estradiol 35mcg/Norethindrone 1mg;Ethinyl Estradiol 20mcg/Norethindrone 1mg
48 Diabetes and Depression in Hispanics and African Americans: Treatment of Depression With Sertraline and Its Effect on A1c and Quality of Life Unknown status NCT00624013 Phase 4 sertraline
49 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram
50 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine

Search NIH Clinical Center for Mood Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: mood disorders

Genetic Tests for Mood Disorder

Anatomical Context for Mood Disorder

MalaCards organs/tissues related to Mood Disorder:

39
Brain, Heart, Testes, Breast, Cortex, Pituitary, Thyroid

Publications for Mood Disorder

Articles related to Mood Disorder:

(show top 50) (show all 801)
id Title Authors Year
1
The association between low level of high-density lipoprotein cholesterol and mood disorder using time-dependent analysis. ( 28843914 )
2018
2
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. ( 28839341 )
2017
3
Facilitators and Barriers to Disclosure of Postpartum Mood Disorder Symptoms to a Healthcare Provider. ( 28766092 )
2017
4
Emotion-related impulsivity and rumination predict the perimenstrual severity and trajectory of symptoms in women with a menstrually related mood disorder. ( 28898408 )
2017
5
Critical exploration of co-occurring Attention-Deficit/Hyperactivity Disorder, mood disorder and Substance Use Disorder. ( 28686107 )
2017
6
Hypersomnolence, Hypersomnia, and Mood Disorders. ( 28243864 )
2017
7
Mood Disorder as an Early Presentation of Epidermoid of Quadrigeminal Cistern. ( 28694630 )
2017
8
Clinical stabilisation with lacosamide of mood disorder comorbid with PTSD and fronto-temporal epilepsy. ( 28845834 )
2017
9
Chronobiological theories of mood disorder. ( 28894915 )
2017
10
Defining melancholia: A core mood disorder. ( 28599349 )
2017
11
Is the association between offspring intelligence and parents' educational attainment influenced by schizophrenia or mood disorder in parents? ( 28868239 )
2017
12
Could EPO studies improve mood disorder treatment strategies? ( 27967254 )
2017
13
Defective compensation over early dysneurogenesis in schizophrenia and mood disorder. ( 28666634 )
2017
14
Mood disorder, anxiety, and suicide risk among subjects with alcohol abuse and/or dependence: a population-based study. ( 28658442 )
2017
15
Creativity and Mood Disorder: A Systematic Review and Meta-Analysis. ( 28934560 )
2017
16
Exploratory Study of the Clinical Characteristics of Adolescent Girls with a History of Physical or Sexual Abuse Consulting in a Mood Disorder Clinic. ( 28747935 )
2017
17
Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. ( 28612214 )
2017
18
Effect of Hypoxic Injury in Mood Disorder. ( 28717522 )
2017
19
The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. ( 28681620 )
2017
20
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. ( 28839340 )
2017
21
Genealogy Study of Three Generations of Patients with Bipolar Mood Disorder Type I. ( 28852243 )
2017
22
Narcissistic Personality Disorder and suicidal behavior in mood disorders. ( 27816770 )
2017
23
Effectiveness evaluation of mood disorder treatment algorithms in Brazilian public healthcare patients. ( 28832750 )
2017
24
Prevalence and predictors of post-stroke mood disorders: A meta-analysis and meta-regression of depression, anxiety and adjustment disorder. ( 28807138 )
2017
25
Branched-Chain Amino Acids as New Biomarkers of Major Depression - A Novel Neurobiology of Mood Disorder. ( 27490818 )
2016
26
Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin. ( 27835716 )
2016
27
Functioning Among Youth with Comorbid Mood Disorder and Chronic Physical Illness in Public Sector Care. ( 27680986 )
2016
28
Association between the 5-HTTLPR Genotype and Childhood Characteristics in Mood Disorders. ( 26792045 )
2016
29
Mortality trends in cardiovascular causes in schizophrenia, bipolar and unipolar mood disorder in Sweden 1987-2010. ( 26748100 )
2016
30
A comparative meta-analysis of TEMPS scores across mood disorder patients, their first-degree relatives, healthy controls, and other psychiatric disorders. ( 26897455 )
2016
31
Circadian Gene Circuitry Predicts Hyperactive Behavior in a Mood Disorder Mouse Model. ( 27028761 )
2016
32
Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder. ( 26896670 )
2016
33
Changes in cortical N-methyl-D-aspartate receptors and post-synaptic density protein 95 in schizophrenia, mood disorders and suicide. ( 26013316 )
2016
34
Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project. ( 26980207 )
2016
35
Presence or absence of cognitive complaints in Parkinson's disease: mood disorder or anosognosia? ( 27332067 )
2016
36
Illness history: Not associated with remission during treatment of major depression in 515 mood disorder patients. ( 26655121 )
2016
37
The Effect of Family-Centered Psycho-Education on Mental Health and Quality of Life of Families of Adolescents with Bipolar Mood Disorder: A Randomized Controlled Clinical Trial. ( 27382589 )
2016
38
Low birth weight and features of neuroticism and mood disorder in 83a88545 participants of the UK Biobank cohort. ( 27703752 )
2016
39
Mood disorders in healthy elderly with obstructive sleep apnea: a gender effect. ( 27198948 )
2016
40
Ultrasonographically Measured Change in Thyroid Status in Lithium Treated Adult Patients with Mood Disorder. ( 27114623 )
2016
41
Melatonin and pro-hypnotic effectiveness of the antidepressant Trazodone: A preliminary evaluation in insomniac mood-disorder patients. ( 27374436 )
2016
42
Exploring the Use of Information and Communication Technology by People With Mood Disorder: A Systematic Review and Metasynthesis. ( 27370327 )
2016
43
Anxiety or agitation in mood disorder with mixed features: A review with a focus on validity as a dimensional criterion. ( 27490837 )
2016
44
Predictors for Reconstruction and Mood Disorder Associated With Reconstruction in Patients With Breast Cancer and Mastectomy: A Retrospective Cohort Study. ( 26817890 )
2016
45
Effect of lithium on thyroid function in adolescents with mood disorder. ( 27931904 )
2016
46
Effect of obesity on cognition in adults with and without a mood disorder: study design and methods. ( 26928024 )
2016
47
A Magnetic Resonance Spectroscopy study of lovastatin for treating Bipolar Mood disorder, A-4 week Randomized Double Blind, Placebo- Controlled Clinical Trial. ( 27804862 )
2016
48
Treatment of Postpartum Mood Disorder in Iran. ( 27903108 )
2016
49
Integrating Early Intervention for Borderline Personality Disorder and Mood Disorders. ( 27144298 )
2016
50
Clinical and genetic factors associated with suicide in mood disorder patients. ( 26626456 )
2016

Variations for Mood Disorder

Expression for Mood Disorder

Search GEO for disease gene expression data for Mood Disorder.

Pathways for Mood Disorder

Pathways related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 28)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.5 CRH DRD2 DRD4 HTR1A HTR1B HTR2A
2
Show member pathways
12.64 CACNA1C COMT CREB1 DRD2 DRD4 MAOA
3 12.53 COMT CREB1 HTR1A NPY POMC TH
4 12.26 CACNA1C CREB1 DRD2 DRD4
6
Show member pathways
12.22 BDNF CACNA1C CREB1 DRD2 HTR1A HTR1B
7
Show member pathways
12.12 CACNA1C CREB1 DRD2 DRD4
8 12.02 BDNF CREB1 HTR1A HTR2A MAOA NR3C1
9
Show member pathways
11.95 DRD2 DRD4 HTR1A HTR1B HTR2A
10
Show member pathways
11.93 BDNF CACNA1C CREB1 DRD2 MAOA MAOB
11
Show member pathways
11.86 DRD2 DRD4 SLC18A2 TH
12 11.78 CREB1 CRH POMC
13 11.76 MAOA TH TPH1
14 11.7 CREB1 NR3C1 POMC
15
Show member pathways
11.7 COMT MAOA MAOB TH
16 11.68 BDNF SLC18A2 TH
17 11.66 CACNA1C HTR1A HTR1B HTR2A MAOA MAOB
18
Show member pathways
11.38 MAOA SLC6A4 TH
19
Show member pathways
11.17 COMT MAOA SLC6A4
20
Show member pathways
11.1 COMT MAOA TH TPH1
21 11.07 CACNA1C NPY SLC18A2
22 10.88 COMT MAOA MAOB TH
23
Show member pathways
10.83 COMT MAOA MAOB
24 10.78 BDNF CREB1
25
Show member pathways
10.74 MAOA MAOB
26 10.7 CACNA1C TH
27 10.61 HTR1A HTR1B HTR2A MAOA SLC18A2 SLC6A4
28 10.44 CRH POMC

GO Terms for Mood Disorder

Cellular components related to Mood Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.56 BDNF COMT CREB1 DISC1 MAOA MAOB
2 axon GO:0030424 9.1 COMT CREB1 DISC1 DRD2 HTR2A TH

Biological processes related to Mood Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.96 CREB1 DRD2 SLC6A4 TH
2 chemical synaptic transmission GO:0007268 9.96 CRH HTR1B HTR2A NPY SLC18A2
3 response to toxic substance GO:0009636 9.88 DRD2 MAOB SLC18A2 SLC6A4
4 locomotory behavior GO:0007626 9.87 DRD2 SLC18A2 TH
5 circadian rhythm GO:0007623 9.87 CREB1 SLC6A4 TPH1
6 positive regulation of fat cell differentiation GO:0045600 9.83 CREB1 HTR2A TPH1
7 social behavior GO:0035176 9.83 DRD4 SLC6A4 TH
8 feeding behavior GO:0007631 9.82 DRD2 HTR1B NPY
9 response to nicotine GO:0035094 9.82 CREB1 DRD2 TH
10 response to cocaine GO:0042220 9.81 CRH DRD2 HTR1B
11 memory GO:0007613 9.76 CREB1 HTR2A SLC6A4 TH
12 response to immobilization stress GO:0035902 9.74 CRH TH TPH1
13 regulation of dopamine secretion GO:0014059 9.72 DRD2 HTR1B HTR2A
14 response to ethanol GO:0045471 9.72 CRH DRD2 HTR1B MAOB TH
15 negative regulation of cAMP biosynthetic process GO:0030818 9.71 DRD4 HTR1B
16 positive regulation of long-term synaptic potentiation GO:1900273 9.71 CREB1 DRD2
17 behavioral response to ethanol GO:0048149 9.71 DRD2 DRD4
18 positive regulation of kinase activity GO:0033674 9.71 DRD4 HTR2A
19 behavioral response to cocaine GO:0048148 9.71 DRD2 DRD4 HTR2A
20 bone remodeling GO:0046849 9.7 HTR1B TPH1
21 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A4 TH
22 negative regulation of voltage-gated calcium channel activity GO:1901386 9.7 DRD2 DRD4
23 synaptic transmission, dopaminergic GO:0001963 9.7 CRH DRD2 TH
24 G-protein coupled receptor internalization GO:0002031 9.69 DRD2 HTR1B
25 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.69 DRD2 DRD4
26 vasoconstriction GO:0042310 9.69 HTR1A HTR1B SLC6A4
27 cellular response to alkaloid GO:0071312 9.68 HTR1B TH
28 catecholamine metabolic process GO:0006584 9.68 COMT MAOA
29 regulation of dopamine metabolic process GO:0042053 9.68 DRD4 HTR1A
30 regulation of appetite GO:0032098 9.68 NPY POMC
31 monoamine transport GO:0015844 9.67 SLC18A2 SLC6A4
32 aromatic amino acid family metabolic process GO:0009072 9.67 TH TPH1
33 response to corticosterone GO:0051412 9.67 CRH MAOB TH
34 regulation of hormone secretion GO:0046883 9.66 HTR1A HTR2A
35 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.65 DRD2 HTR1B HTR2A
36 negative regulation of serotonin secretion GO:0014063 9.63 HTR1B MAOB
37 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.63 HTR1A HTR1B
38 serotonin receptor signaling pathway GO:0007210 9.62 HTR1A HTR2A
39 response to ether GO:0045472 9.62 CRH TH
40 aminergic neurotransmitter loading into synaptic vesicle GO:0015842 9.61 SLC18A2 TH
41 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.61 DRD2 DRD4
42 dopamine metabolic process GO:0042417 9.61 COMT DRD2 DRD4
43 serotonin transport GO:0006837 9.6 SLC18A2 SLC6A4
44 response to histamine GO:0034776 9.59 DRD2 DRD4
45 regulation of serotonin secretion GO:0014062 9.58 CRH HTR1A
46 neurotransmitter catabolic process GO:0042135 9.58 COMT MAOA MAOB
47 regulation of behavior GO:0050795 9.54 HTR1A HTR1B HTR2A
48 response to amphetamine GO:0001975 9.46 DRD2 DRD4 SLC18A2 TH
49 dopamine catabolic process GO:0042420 9.43 COMT MAOA MAOB
50 response to drug GO:0042493 9.28 COMT CREB1 CRH DRD2 HTR1B HTR2A

Molecular functions related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.91 DRD2 DRD4 HTR1A HTR1B HTR2A
2 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.52 DRD2 DRD4
3 neurotransmitter receptor activity GO:0030594 9.5 HTR1A HTR1B HTR2A
4 monoamine transmembrane transporter activity GO:0008504 9.49 SLC18A2 SLC6A4
5 primary amine oxidase activity GO:0008131 9.48 MAOA MAOB
6 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD2 DRD4
7 drug binding GO:0008144 9.46 DRD2 DRD4 HTR1B HTR2A
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.43 TH TPH1
9 G-protein coupled serotonin receptor activity GO:0004993 9.43 HTR1A HTR1B HTR2A
10 serotonin transmembrane transporter activity GO:0015222 9.4 SLC18A2 SLC6A4
11 neuropeptide hormone activity GO:0005184 9.37 CRH NPY
12 dopamine binding GO:0035240 9.13 DRD2 DRD4 TH
13 serotonin binding GO:0051378 8.8 HTR1A HTR1B HTR2A
14 G-protein coupled receptor activity GO:0004930 10.01 DRD2 DRD4 HTR1A HTR1B HTR2A NPY

Sources for Mood Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
20